Compare Amylx Pharmaceuticals Inc (AMLX) vs SkyWest Inc (SKYW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs SkyWest Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while SkyWest Inc trades at $99.72 (market cap $3.96B). The key difference: SkyWest Inc is far larger — about 2× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, SkyWest Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | SKYW | |
|---|---|---|
Market Cap | $1.98B | $3.96B |
Sector | Health | Technology |
52-Week High | $18.70 | $123.72 |
52-Week Low | $7.64 | $78.40 |
Enterprise Value | $1.70B | $5.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
SkyWest (SKYW) trades at $99.72, down 0.29% on the day, with strong technical momentum showing bullish moving averages and key support at $98. The company maintains solid fundamentals with a P/E of 9.57, net income margin of 10.42%, and consistent earnings beats in recent quarters. Recent leadership changes include Wade Steel's promotion to President and COO of SkyWest Airlines.
SkyWest presents attractive valuation with upside to the $109.33 consensus price target, supported by strong analyst sentiment (56% buy ratings). Key risks include rising fuel costs highlighted in recent government data showing 84% year-over-year increases, which could pressure airline profitability despite current operational strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
